| BOUCHAL, Pavel, Jiří JARKOVSKÝ, Kristýna HRAZDILOVÁ, Monika DVOŘÁKOVÁ, Iva STRUHÁROVÁ, Lenka HERNYCHOVÁ, Jiří DAMBORSKÝ, Petr SOVA a Bořivoj VOJTĚŠEK. The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo. Proteome Science. BioMed Central, 2011, roč. 9, č. 68, s. "nestránkováno", 9 s. ISSN 1477-5956. Dostupné z: https://dx.doi.org/10.1186/1477-5956-9-68. |
Další formáty:
BibTeX
LaTeX
RIS
@article{958893,
author = {Bouchal, Pavel and Jarkovský, Jiří and Hrazdilová, Kristýna and Dvořáková, Monika and Struhárová, Iva and Hernychová, Lenka and Damborský, Jiří and Sova, Petr and Vojtěšek, Bořivoj},
article_number = {68},
doi = {http://dx.doi.org/10.1186/1477-5956-9-68},
keywords = {(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12); plasma retinol-binding protein 4; RBP4; cisplatin; adamantylamine; proteomics},
language = {eng},
issn = {1477-5956},
journal = {Proteome Science},
title = {The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo},
url = {http://www.proteomesci.com/content/9/1/68},
volume = {9},
year = {2011}
}
TY - JOUR
ID - 958893
AU - Bouchal, Pavel - Jarkovský, Jiří - Hrazdilová, Kristýna - Dvořáková, Monika - Struhárová, Iva - Hernychová, Lenka - Damborský, Jiří - Sova, Petr - Vojtěšek, Bořivoj
PY - 2011
TI - The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo
JF - Proteome Science
VL - 9
IS - 68
SP - "nestránkováno"
EP - "nestránkováno"
PB - BioMed Central
SN - 14775956
KW - (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12)
KW - plasma retinol-binding protein 4
KW - RBP4
KW - cisplatin
KW - adamantylamine
KW - proteomics
UR - http://www.proteomesci.com/content/9/1/68
L2 - http://www.proteomesci.com/content/9/1/68
N2 - Background: The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine) amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and therapy monitoring. Methods: Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman correlation analysis. Results: We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats. Similar results were observed in randomly selected patients involved in Phase I clinical trials. Conclusions: RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin.
ER -
BOUCHAL, Pavel, Jiří JARKOVSKÝ, Kristýna HRAZDILOVÁ, Monika DVOŘÁKOVÁ, Iva STRUHÁROVÁ, Lenka HERNYCHOVÁ, Jiří DAMBORSKÝ, Petr SOVA a Bořivoj VOJTĚŠEK. The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo. \textit{Proteome Science}. BioMed Central, 2011, roč.~9, č.~68, s.~''nestránkováno'', 9 s. ISSN~1477-5956. Dostupné z: https://dx.doi.org/10.1186/1477-5956-9-68.
|
